Alkem Laboratories

Alkem launches novel antibiotic combination for drug-resistant infections

The formulation, to be sold under the Zidavi brans for Rs 2,700 a vial, has been approved by US FDA, European Medicines Agency, and CDSCO

Enzene Biosciences raises $50 million, aims to expand into global markets

Enzene said it has built a highly experienced 400-person team under the leadership of Dr. Himanshu Gadgil, CEO at Enzene Biosciences Ltd

Stocks to watch: M&M, Eicher Motors, Zomato, Adani Green, Alkem Labs, JSPL

Stocks to watch today: LIC, M&M, Adani Power, Hindalco Industries will report the July-September (Q2FY23) quarter results on Friday, November 11

USFDA issues Form-483 with 3 observations to Alkem Lab's St Louis plant

Alkem Laboratories on Thursday said the US health regulator has issued three observations after inspecting its St Louis-based manufacturing facility. The US Food and Drug Administration (USFDA) had conducted a pre-approval inspection at the plant from October 31, 2022 to November 9, 2022, the drug firm said in a regulatory filing. At the end of the inspection, the company received Form 483 with three observations, it added. "There is no data integrity observation. This pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline, a detailed response to close out the said observations," the company said. As per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

HUL, Asian Paints: 5 stocks withstood recent sell-off; Will they rise more?

Among individual stocks, Asian Paints, EIH and Alkem Laboratories can rally up to 18 per cent each. Hindustan Unilever and Metro Brands too are poised to log smart gains, indicate charts.

India's first off-the-shelf cell therapy treatment for knee osteoarthritis

One injection will cost Rs 1.25 lakh with effects lasting for two years or more

Indian pharma industry may rebound to 8-11% growth rate, says Alkem

Alkem Laboratories expects the Indian pharmaceutical industry to rebound to 8-11 per cent growth rate with normalcy in activities as the pandemic eases out

IIFL Securities pays over Rs 2 cr to settle case with Sebi

It was alleged that IIFL Wealth Management Ltd and IIFL Securities Ltd knowingly manipulated the reference price of Alkem Laboratories for a block deal

BSE Healthcare index up 2%; Cipla, Alkem, Dr.Reddy's rally up to 8%

The pharma index had taken a breather over the past three months after displaying relative out-performance during CY20-21.

Q2 preview: Non-Covid revenues to hint at normalisation for healthcare cos

Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages

Here is a Bull Spread Strategy on Alkem Labs by Nandish Shah of HDFC Sec

The stock price of Alkem Laboratories has broken out on the daily chart

Here's a derivative strategy on Alkem Lab by Nandish Shah of HDFC Sec

The stock price has already broken out on the daily chart to close at an all-time high with higher volumes

Double-digit sales dip in anti-infective segment to weigh on Alkem Labs

Higher chronic sales, US market could offset some of the weakness in sales growth

Alkem Lab jumps 4.5% as it launches Favipiravir drug to treat Covid-19

Alkem Laboratories has launched Favipiravir under the brand name 'Alfluenza' in India for the management of mild to moderate cases of Covid-19

Antiviral drugs see demand surge in India, but segment declines 5.5%

Data from market research firm AIOCD-AWACS shows that sales of oseltamivir (common brand Tamiflu), used against the influenza virus and also for swine flu, went up by 35.8 per cent in April

Alkem Laboratories gets EIR from USFDA for manufacturing facility at Baddi

The USFDA has now issued an EIR for the manufacturing facility, it added.

CCI warns drugmakers not to indulge in unfair business practices

CCI said it has passed an order against the entities for violating provisions of the Competition Act by involving in anti-competitive business practices.

Alkem Labs hits record high, soars 8% on strong Q3 results, dividend bounty

The board of directors of the company has declared an interim dividend of Rs 22 per equity share for the financial year 2019-20.

Near-term overhang for Alkem Laboratories' fast growing US business

Any adverse outcome of the FDA's observations will impact the company's overall growth

Alkem Labs dips 11% as USFDA issues 13 observations for Daman facility

The stock dipped 11% to Rs 1,858 on the BSE in intra-day trade on back of heavy volumes.